Will New Injection Devices for Interferon Beta-1a s.c. Affect Treatment Adherence in Patients With Multiple Sclerosis? An Expert Opinion in the Middle East

REFERENCES

• Al-Sabbagh, A., Bennett, R., Kozma, C., Dickson, M., & Meletiche, D. (2008). Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. 18th meeting of the ENS, Monday 9 June, Poster 321.
   Google Scholar
• Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Brod, M., (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes, 2, 12.
   PubMedGoogle Scholar
• Brochet, B., Lemaire, G., & Beddiaf, A. (2006). Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Revue Neurologique (Paris), 162, 735–740.
   PubMed Web of Science ®Google Scholar
• Clanet, M., Kappos, L., Hartung, H. P., & Hohlfeld, R. (2004). Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Multiple Sclerosis, 10, 139–144.
   PubMed Web of Science ®Google Scholar
• Cohen, B. A. (2006). Adherence to disease-modifying therapy for multiple sclerosis. International Journal of Multiple Sclerosis Care, (Suppl), 32–37.
   Google Scholar
• Cohen, B. A., & Rieckmann, P. (2007). Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice, 61, 1922–1930.
   PubMed Web of Science ®Google Scholar
• Conlin, P. R., Gerth, W. C., Fox, J., Roehm, J. B., & Boccuzzi, S. J. (2001). Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics, 23, 1999–2010.
   PubMed Web of Science ®Google Scholar
• Cox, D., & Stone, J. (2006). Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. The Journal of Neuroscience Nursing, 38, 167–171.
   PubMedGoogle Scholar
• Cramer, J. A., Cuffel, B. J., Divan, V., Al-Sabbagh, A., & Glassman, M. (2006). Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurologica Scandinavica, 113, 156–162.
   PubMed Web of Science ®Google Scholar
• Dahlgren, J. (2008). Easypod: A new electronic injection device for growth hormone. Expert Review of Medical Devices, 5, 297–304.
   PubMed Web of Science ®Google Scholar
• Devonshire, V., Lapierre, Y., Macdonell, R., Ramo-Tello, C., Patti, F., Fontoura, P., (2010). The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology, Vol 10, DOI: 10.1111/j.1468-1331.2010.03110.x.
   Google Scholar
• Devonshire, V., Verdun, E., on behalf of the RebiSmart™ User Trial study group. (2009). Delivery technology for multiple sclerosis therapy: An international, multicentre, single-arm, open-label, 12-week, Phase IIIb trial of a new electronic device for subcutaneous injection of interferon beta-1a. 19th Meeting of the European Neurological Society (ENS), Milan, Italy, 20–24 June, Poster 698.
   Google Scholar
• Dupclay, L., Jr., & Doyle, J. (2002). Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. American Journal of Managed Care, 8, S335–S340.
   PubMed Web of Science ®Google Scholar
• Giovannoni, G., Barbarash, O., Casset-Semanaz, F., King, J., Metz, L., Pardo, G., (2009). Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis, 15, 219–228.
   PubMed Web of Science ®Google Scholar
• IFNB MS Study group. (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology, 45, 1277–1285.
   PubMed Web of Science ®Google Scholar
• Jaber, A., Bozzato, G. B., Vedrine, L., Prais, W. A., Berube, J., & Laurent, P. E. (2008). A novel needle for subcutaneous injection of interferon beta-1a: Effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurology, 8, 38.
   PubMed Web of Science ®Google Scholar
• Kappos, L., Traboulsee, A., Constantinescu, C., Eralinna, J. P., Forrestal, F., Jongen, P., (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, 67, 944–953.
   PubMed Web of Science ®Google Scholar
• Lugaresi, A., Durastanti, V., Gasperini, C., Lai, M., Pozzilli, C., Orefice, G., (2008). Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: The CoSa study. Clinical Neuropharmacology, 31, 167–172.
   PubMed Web of Science ®Google Scholar
• Mikol, D., Lopez-Bresnahan, M., Taraskiewicz, S., Chang, P., & Rangnow, J. (2005). A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Multiple Sclerosis, 11, 585–591.
   PubMed Web of Science ®Google Scholar
• Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125–132.
   PubMed Web of Science ®Google Scholar
• O'Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Multiple Sclerosis, 11, 46–50.
   PubMed Web of Science ®Google Scholar
• Partridge, A. H., Avorn, J., Wang, P. S., & Winer, E. P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652–661.
   PubMed Web of Science ®Google Scholar
• Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306–309.
   PubMed Web of Science ®Google Scholar
• Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43, 521–530.
   PubMed Web of Science ®Google Scholar
• Stone, V. E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865–872.
   PubMed Web of Science ®Google Scholar
• Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology, 61, 551–554.
   PubMed Web of Science ®Google Scholar
• Williams, M., Clarke, T., Williams, P., & Barton, E. N. (2007). The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. West Indian Medical Journal, 56, 270–274.
   PubMedGoogle Scholar
• World Health Organization. (2003). Adherence to long-term therapies. Evidence for action. WHO. www.iMED.org iMED.org accessed 14/09/10.
   Google Scholar
• Yamout, B. I., Dahdaleh, M., Al Jumah, M. A., Al-Shammri, S., Al Sharoqi, I., Al-Tahan, A. R., (2010). Adherence to disease-modifying drugs in patients with multiple sclerosis: A consensus statement from the Middle East MS Advisory Group. International Journal of Neuroscience, 120, 273–279.
   PubMed Web of Science ®Google Scholar